HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

Slides:



Advertisements
Similar presentations
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Advertisements

Pathogenesis and Control of Viral Infections Chapter 30.
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Treatment of AIDS “Antiretroviral therapy & vaccines”
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
The branch that breaks Is called rotten, but Wasn’t there snow on it? Bartolt Brecht Haiti after a hurricane.
Bioe 109 Evolution Summer 2009 Lecture 1: Part II Evolution in action: the HIV virus.
Dr. Abdulkarim Alhethail
Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.
The branch that breaks Is called rotten, but Wasn’t there snow on it? Bartolt Brecht Haiti after a hurricane.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
KITSO AIDS Training Program
Viruses that Use Reverse Transcriptase during Replication The retroviruses have an RNA genome that is converted to DNA by RT after infection. The hepadnaviruses.
Vaccines Polio - close to eradication. In 2001 >1000 cases worldwide; last wild case in Americas in Peru in 1991.
KITSO AIDS Training Program
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
How HIV affects the Immune System. INTRODUCTION HIV attacks and kills crucial immune system cells, known as T-helper cells. Without T-helper cells many.
Immunity and Infection Chapter 17. The Chain of Infection  Transmitted through a chain of infection (six links) ◦ Pathogen: ◦ Reservoir: ◦ Portal of.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Plate 87 Acquired Immune Deficiency Syndrome (AIDS)
Viruses Chapter Nature of Viruses All viruses have same basic structure -Nucleic acid core surrounded by capsid Nucleic acid can be DNA or RNA;
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
HIV and AIDS Are HIV and AIDS the same thing?. HIV HIV – Human Immunodeficiency Virus HIV – Human Immunodeficiency Virus A pathogen (virus) that destroys.
The evolution of HIV Why is HIV fatal?. Lethal strains are favored, due to “Short sighted” evolution within hosts Transmission rate advantages.
HIV Cellular Pathogenesis III
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Detecting Infectious HIV in Human Milk Miles W. Cloyd, Ph.D. Professor Department of Microbiology & Immunology University of Texas Medical Branch Galveston,
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Immunology of HIV Infection Michael F. Para, MD Professor of Internal Medicine Division of Infectious Diseases 1 1.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Evolution is the unifying concept of biology. Two Central Themes of Biology Adaptation - How and in what ways do organisms function and become better.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
Chapter 47 Section 3 pp HIV AND AIDS. VACCINES  Vaccines artificially produce acquired immunity  Vaccine- substance that contains antigen.
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Retrovirus. Retroviridae –Retrovirus HTLV (human T-cell lymphotropic virus) –Lentivirus HIV.
HIV/AIDS.
Phar. Nhat Mang/ Roche Vietnam
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
IMMUNODEFICIENCIES HIV2 324 PHT Dr. Sarah I. Bukhari PhD in Clinical Microbiology Department of Pharmaceutics Office: rd floor
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
HIV Cure: Current Status and Future Perspectives
Human Immunodeficiency virus HIV Retroviridae R
Feedback meeting September 2017
Viruses Chapter 17.
Immunodeficiency (2 of 2)
Immunodeficiency (2 of 2)
Keep control: Elite and post-treatment controllers
Presentation transcript:

HIV Cellular Pathogenesis III Benhur Lee, M.D.

Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load

Viral load “set-point” is a major determinant of disease progression “Set-point” determined by a balance between the virulence of the viral strain and the quality/strength of host immune response

Control of HIV replication and disease progression by balance of host factors

Viral load “set-point” is a major determinant of disease progression “Set-point” determined by a balance between the virulence of the viral strain and the quality/strength of host immune response

Viral Load is a stronger and more independent predictor of disease progression than CD4 count

Viral Load Tests Quantitative (Viral Load determination) Quantitative RT-PCR (<2x x10 6 ) Most sensitive for low levels of viral RNA Requires ~200  l of blood Branched chain DNA (<5x x10 6 ) Most accurate for high levels of viral RNA Requires ~2 ml of blood NASBA (Nucleic Acid Based Sequence Amplification) (<4x x10 6 ) Clinical interpretation of Viral Load must take into account the type of assay used. Inter-assay differences can differ by as much a 0.5 log.

Combination anti-viral Rx can reduced viral loads down to undetectable levels (<50 copies /ml) RT Pr

RT Inhibitors Protease Inhibitors Entry Inhibitors Synergism (Fuzeon™)

Log Viral Load Phase 1: Exponential Decay Phase 2: Linear Decay Phase 3: t 1/2 of this phase can be used to approximate treatment time for eradication

} Latently Infected Cells --turnover is very slow --relatively resistant to anti-viral Rx

CCR5++ CCR5+ Activation Step Is critical for recovery of virus from latent reservoir CCR5- CCR5++ Viral Eradication may require repeated “flush and kill” regimens How do we determine the number of latently infected cells if (1) Latently infected cells are so rare, and (2) Virus is not replicating in latently infected cells

Isolate highly purified CD4+ Naïve T-cells CD4+, CD3+, CD25-. CD69-, HLA-DR- (Activation Markers) <0.01% of resting T-cells are latently infected Limiting Dilution 5 x x x x x 10 3 Activation add PHA, add CD4+ T cells from HIV-negative donor to rescue virus Detect viral replication on day 7-9, back-calculate IUPM based on lowest dilution from which virus can be rescued

5 x x x x x IUPM > Time on HAART Key: (+) = virus replication detected (- ) = no virus replication detected Increasing time

Is Eradication Possible? Rx period>67 years

Mechanism for persistance of latent reservoir Stability reflects basic biology of memory T cells Long lived immunity (resting T cells) HepC and Measles specificT cells can be detected >20 years after primary infection Half life of memory T cells (>6 months) Viremia is NOT completely eliminated Undetectable viral load = No viral replication Continual low-level infection of T cells, replenishment of latent reservoir How does one determine low level of viral replication below limits of detection?

Eradication of Viral Reservoirs Treatment Intensification--5-drug HAART “ Flushing out” latent virus T cell activation Structured Treatment Interruptions “Autoimmunization” (no longer recommended)

North America

Challenges for an AIDS Vaccine Antibody response Elicitation of Abs towards neutralizing epitopes (conserved) Oligomeric vs monomeric Env response CTL response Conserved CTL epitopes Neutralization Escape mutants Sustaining the response (live viral vectors)